Connect your AI

Ultragenyx Pharmaceutical RARE Price / sales

Price / sales at other companies

Eli LillyLLY

11.4×-3.8×

AmgenAMGN

5.1×+0.2×

Ionis PharmaceuticalsIONS

11.7×+5.0×

Arrowhead ResearchARWR

14.1×+10.9×

CRISPR TherapeuticsCRSP

1,112.8×+1,035×

ModernaMRNA

9.1×+5.6×

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

market cap/total revenue=3.1×

Based on the most recent quarter.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's price / sales?: Ultragenyx Pharmaceutical (RARE) reported price / sales of 3.1× in Q1 2026.
How has Ultragenyx Pharmaceutical's price / sales changed year-over-year?: Ultragenyx Pharmaceutical's price / sales decreased by 46.6% year-over-year, from 5.8× to 3.1×.
What is the long-term trend for Ultragenyx Pharmaceutical's price / sales?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's price / sales has grown at a -37.6% compound annual growth rate (CAGR), from 34.8× to 3.3×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.